Literature DB >> 24672140

Lead Diversification through a Prins-Driven Macrocyclization Strategy: Application to C13-Diversified Bryostatin Analogues.

Paul A Wender1, Kelvin L Billingsley2.   

Abstract

The design, synthesis, and biological evaluation of a novel class of C13-diversified bryostatin analogues are described. An innovative and general strategy based on a Prins macrocyclization-nucleophilic trapping cascade was used to achieve late-stage diversification. In vitro analysis of selected library members revealed that modification at the C13 position of the bryostatin scaffold can be used as a diversification handle to regulate biological activity.

Entities:  

Keywords:  cyclizations; drugs; macrocycles; polyketides

Year:  2013        PMID: 24672140      PMCID: PMC3963460          DOI: 10.1055/s-0033-1338860

Source DB:  PubMed          Journal:  Synthesis (Stuttg)        ISSN: 0039-7881            Impact factor:   3.157


  48 in total

1.  Total synthesis of the cyanolide A aglycon.

Authors:  Michael R Gesinski; Scott D Rychnovsky
Journal:  J Am Chem Soc       Date:  2011-06-08       Impact factor: 15.419

2.  A concise, selective synthesis of the polyketide spacer domain of a potent bryostatin analogue.

Authors:  Paul A Wender; Alexander V W Mayweg; Christopher L VanDeusen
Journal:  Org Lett       Date:  2003-02-06       Impact factor: 6.005

3.  Total synthesis of bryostatin 1.

Authors:  Gary E Keck; Yam B Poudel; Thomas J Cummins; Arnab Rudra; Jonathan A Covel
Journal:  J Am Chem Soc       Date:  2010-12-22       Impact factor: 15.419

4.  Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin.

Authors:  Paul A Wender; Vishal A Verma
Journal:  Org Lett       Date:  2006-04-27       Impact factor: 6.005

5.  A Sakurai-Prins-Ritter sequence for the three-component diastereoselective synthesis of 4-amino tetrahydropyrans.

Authors:  Oleg L Epstein; Tomislav Rovis
Journal:  J Am Chem Soc       Date:  2006-12-27       Impact factor: 15.419

6.  Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90.

Authors:  Iwona E Wrona; Alexander Gozman; Tony Taldone; Gabriela Chiosis; James S Panek
Journal:  J Org Chem       Date:  2010-05-07       Impact factor: 4.354

7.  Enantioselective total synthesis of (-)-zampanolide, a potent microtubule-stabilizing agent.

Authors:  Arun K Ghosh; Xu Cheng
Journal:  Org Lett       Date:  2011-07-12       Impact factor: 6.005

8.  Total synthesis and structure-activity investigation of the marine natural product neopeltolide.

Authors:  Daniel W Custar; Thomas P Zabawa; John Hines; Craig M Crews; Karl A Scheidt
Journal:  J Am Chem Soc       Date:  2009-09-02       Impact factor: 15.419

Review 9.  Function-oriented synthesis, step economy, and drug design.

Authors:  Paul A Wender; Vishal A Verma; Thomas J Paxton; Thomas H Pillow
Journal:  Acc Chem Res       Date:  2007-12-27       Impact factor: 22.384

10.  Total synthesis and structural revision of the marine macrolide neopeltolide.

Authors:  Daniel W Custar; Thomas P Zabawa; Karl A Scheidt
Journal:  J Am Chem Soc       Date:  2008-01-23       Impact factor: 15.419

View more
  3 in total

1.  Toward the Ideal Synthesis and Transformative Therapies: The Roles of Step Economy and Function Oriented Synthesis.

Authors:  Paul A Wender
Journal:  Tetrahedron       Date:  2013-06-07       Impact factor: 2.457

2.  Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.

Authors:  Brian A Loy; Adam B Lesser; Daryl Staveness; Kelvin L Billingsley; Lynette Cegelski; Paul A Wender
Journal:  J Am Chem Soc       Date:  2015-03-04       Impact factor: 15.419

3.  A practical way to synthesize chiral fluoro-containing polyhydro-2H-chromenes from monoterpenoids.

Authors:  Oksana S Mikhalchenko; Dina V Korchagina; Konstantin P Volcho; Nariman F Salakhutdinov
Journal:  Beilstein J Org Chem       Date:  2016-04-06       Impact factor: 2.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.